SRBD1

Across TCGA pan-cancer cohorts, SRBD1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SRBD1 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher SRBD1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SRBD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, LUSC, and UCEC are the cancer types where SRBD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.180	0.796	.001	30	view →
LUSC	DFS	Median	III,IV	0.011	0.665	<.001	24	view →
UCEC	DFS	Median	All	0.973	0.827	.012	18	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	6	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SRBD1–KIRC (DFS)

Open the KIRC breakdown →